Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results for quarter ended June 30, 2026.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended June 30, 2026
- Earnings details furnished in Exhibit 99.1 press release
- Results announcement dated August 10, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $14.4M, down from $18.3M, reflecting lower AbbVie MAVYRET/MAVIRET sales
- Net loss $19.5M, or $0.67 per diluted share, versus $18.3M and $0.85 in Q3 2025
- Cash and marketable securities $211.5M, with funding expected into fiscal 2029
- Zelicapavir pediatric dosing initiated; registrational RESOLVE Phase 2b/3 trial targeted for Q4 2026
- Key 2026 catalysts include EDP-978 Phase 1 data, EPS-3903 IND filing, and MRGPRX2 candidate selection
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.